Study S001062

Improving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Introducing Correction of Metabolism With Glucagon-like Peptide 1 (GLP-1) Drugs

ClinicalTrials.gov record Informed Consent Form (PDF)

Registration

Registration: NCT07303556
Acronym: ICDDTKZ26
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 120
Start: 2024-12-18
Primary completion: 2025-07-01
Lead sponsor: Nazarbayev University
Conditions: Heart Failure; Diabete Type 2; Arterial Hypertension
Interventions: DRUG:Tirzepatide (Mounjaro); DRUG:dapagliflozin, empagliflozin, metformin
Results posted: FALSE

Registered primary outcomes

Change in NT-proBNP levels from baseline to Week 24 [Baseline to Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.